LCK and chronic myelogenous leukemia, BCR-ABL1 positive: While the LCK inhibitor A-770041 showed in vitro activity comparable to the pan-Src family kinase inhibitor dasatinib, the latter has a higher potency and is already clinically approved for the treatment of CML and ALL.